1. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV

   • Hiroaki Akamatsu
   • Kiichiro Ninomiya
   • Nobuyuki Yamamoto

   Special Article Open access 02 May 2019 Pages: 731 - 770

   

2. Molecular carcinogenesis of gastric cancer: Lauren classification, mucin phenotype expression, and cancer stem cells

   • Naohide Oue
   • Kazuhiro Sentani
   • Wataru Yasui

   Invited Review Article 12 April 2019 Pages: 771 - 778

   

3. Dawn of precision medicine on gastric cancer

   • Takahiro Ishii
   • Akihito Kawazoe
   • Kohei Shitara

   Invited Review Article 11 April 2019 Pages: 779 - 788

4. Induction TPF chemotherapy followed by CRT with fractionated administration of cisplatin in patients with unresectable locally advanced head and neck cancer

   • Susumu Okano
   • Tomohiro Enokida
   • Makoto Tahara

   Original Article 22 February 2019 Pages: 789 - 797

   

5. A prognostic parameter in advanced non-small cell lung cancer: the ratio of hemoglobin-to-red cell distribution width

   • Yakup Bozkaya
   • Bediz Kurt
   • Fatih Gürler

   Original Article 19 February 2019 Pages: 798 - 806

   

6. Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients

   • Rurina Watanuki
   • Tetsu Hayashida
   • Yuko Kitagawa

   Original Article 27 February 2019 Pages: 807 - 814

   

7. Discrimination between breast invasive ductal carcinomas and benign lesions by optimizing quantitative parameters derived from dynamic contrast-enhanced MRI using a semi-automatic method

   • Jiawen Yang
   • Jiandong Yin

   Original Article 27 February 2019 Pages: 815 - 824

   

8. Inflammation–nutrition score predicts prognosis of patients with resectable hepatocellular carcinoma

   • Xiao-Chun Ni
   • Jie Xu
   • Shuang-Jian Qiu

   Original Article 24 April 2019 Pages: 825 - 835

   

9. Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treated metastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the efficacy and safety

   • Hiroaki Tanioka
   • Michitaka Honda
   • Hideyuki Mishima

   Original Article 18 February 2019 Pages: 836 - 841

   

10. Comparative assessment of prognostic outcomes between first-generation antiandrogens and novel androgen-receptor-axis-targeted agents in patients with non-metastatic castration-resistant prostate cancer

    • Hideaki Miyake
    • Yuto Matsushita
    • Atsushi Otsuka

    Original Article 09 February 2019 Pages: 842 - 847

    

11. Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study

    • Taro Iguchi
    • Satoshi Tamada
    • Tatsuya Nakatani

    Original Article 11 February 2019 Pages: 848 - 856

    

12. Oncologic and reproductive outcomes of cystectomy as a fertility-sparing treatment for early-stage epithelial ovarian cancer

    • Hiroaki Kajiyama
    • Shiro Suzuki
    • Fumitaka Kikkawa

    Original Article 15 February 2019 Pages: 857 - 862

    

13. Long-term outcomes and prognostic factors of pulmonary metastasectomy for osteosarcoma and soft tissue sarcoma

    • Yoko Yamamoto
    • Ryu Kanzaki
    • Meinoshin Okumura

    Original Article 26 February 2019 Pages: 863 - 870

    

14. Analysis of major BCR-ABL1 mRNA by digital polymerase chain reaction is useful for prediction of international scale

    • Daisuke Furuya
    • Mikako Moriai
    • Satoshi Takahashi

    Original Article 23 February 2019 Pages: 871 - 875

    

15. Use of direct oral anti-coagulants for the treatment of venous thromboembolism in patients with advanced cancer: a prospective observational study

    • Takuya Oyakawa
    • Nao Muraoka
    • Keita Mori

    Original Article 12 February 2019 Pages: 876 - 881